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OBJECTIVES: High-throughput mass spectrometry methods have been developed to screen newborns for
lysosomal storage disorders, allowing the implementation of newborn screening pilot studies in North America
and Europe. It is currently feasible to diagnose Pompe, Fabry, Gaucher, Krabbe, and Niemann-Pick A/B diseases,
as well as mucopolysaccharidosis I, by tandem mass spectrometry in dried blood spots, which offers
considerable technical advantages compared with standard methodologies. We aimed to investigate whether
the mass spectrometry methodology for lysosomal storage disease screening, originally developed for
newborns, can also discriminate between affected patients and controls of various ages.
METHODS: A total of 205 control individuals were grouped according to age and subjected to mass
spectrometry quantification of lysosomal a-glucosidase, b-glucocerebrosidase, a-galactosidase, acid sphingo-
myelinase, galactocerebrosidase, and a2L-iduronidase activities. Additionally, 13 affected patients were
analyzed.
RESULTS: The median activities for each enzyme and each age group were determined. Enzyme activities were
significantly lower in individuals aged older than 18 years compared with those in newborns. Affected patients
presented enzymatic activities corresponding to less than 20% of the age-matched controls.
CONCLUSIONS: Our data indicate that the mass spectrometry methodology can be used for the screening of
lysosomal storage diseases in non-newborn patients. However, for some diseases, such as Fabry and
mucopolysaccharidosis I, a combination of biochemical and clinical data may be necessary to achieve accurate
diagnoses.
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& INTRODUCTION
Lysosomal storage diseases (LSDs) consist of approxi-
mately 50 genetic disorders, which have a combined
prevalence of 1:7,000,8,000 live births (1). These conditions
are caused mainly by mutations in genes encoding enzymes
or other essential proteins involved in the lysosomal
degradation of intermediate metabolites (2). The progressive
accumulation of these molecules leads to cellular destruc-
tion, which may cause tissue and organ dysfunction (2,3).
Diagnosing this group of diseases is, in many cases,
challenging. The age of onset of clinical manifestations and
rate of substrate accumulation are variable, even among
patients with identical genotypes (4). Nevertheless, these
conditions should be diagnosed as soon as possible, for
early therapeutic interventions have been considered
beneficial to patients. Newborn screening (NBS) for LSDs
by tandem mass spectrometry (MS/MS) has been imple-
mented in North America and European countries as pilot
projects (5-7). Early detection of LSDs in newborns,
especially in Latin America, will take many years before a
considerable fraction of the population is covered (8). Up
until then, inexpensive and high throughput biochemical
assays that can reliably diagnose infants, children and
adults would be desirable.
The introduction of MS/MS assays for the measurement
of lysosomal enzyme activities in dried blood spots (DBSs)
combined sensitivity and specificity with high throughput
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(9). The current study addresses the implementation of the
detection of LSDs by MS/MS in the Sarah Network of
Rehabilitation Hospitals in a non-newborn population in
Brazil. Patients were screened for Pompe (GAA), Gaucher
(ABG), Fabry (GLA), Niemann-Pick A/B (ASM), and
Krabbe (GALC) diseases, as well as MPS I (IDUA). An
adapted version of the NBS methodology was employed
and validated using DBSs of the CDC Quality Assurance
Program (9,10). The median activities of these enzymes in
control individuals were determined, and patients present-
ing with Pompe, Krabbe, Fabry, Gaucher, and MPS I
diseases were also evaluated. To the authors’ knowledge,
this is the first report concerning the screening of LSDs by
MS/MS in Brazil.
& MATERIALS AND METHODS
Reagents
Reagents were purchased from Sigma Chemical Co. (St.
Louis, MO, USA). The enzyme substrates (S) and internal
standards (IS) were kindly donated by the Newborn
Screening Translation Research Initiative (NSTRI) at the
North American Center for Disease Control (CDC, Atlanta,
USA).
Subjects
A total of 205 control patients were divided according to
age into 5 groups: 50 newborn patients, 32 patients aged 1
month to 5 years, 35 patients aged 5 to 10 years, 23 patients
aged 10 to 18 years, and 65 patients aged 18 to 77 years.
Thirteen affected patients diagnosed at our institution by
classic fluorimetric methods, as well as DBSs from three
other genetics services in Brazil, were used as positive
controls. Informed consent was obtained from all the
patients. This research was approved by the ethics
committee of the Sarah Network of Hospitals.
Enzyme assays
An adapted version of the original methodology described
in the literature was used (9,11). Assay cocktails were
prepared by resuspending vials containing substrates and
internal standards for GAA, GLA, ABG, ASM, IDUA, and
GALC according to the supplied instructions. DBS extraction
and incubation with enzyme substrates were performed as
instructed, with the following modifications. We used
Eppendorf tubes instead of 96-well plates, and solid phase
extraction was performed using Strata SI-1 (Phenomenex,
Torrance, CA, USA) and a Visiprep 24-port vacuummanifold
(Sigma). Electrospray ionization mass spectrometry (ESI-
MS/MS) analyses were performed using an API 3200 triple
quadrupole instrument (AB Sciex, Framingham, MA, USA)
in the positive-ion, multiple-reaction monitoring mode.
Blank DBSs, as well as quality control materials, were
assayed (10). Enzyme activities were expressed as mmol/h/L.
Statistical analyses were performed using SPSS ver. 21.
& RESULTS
Assay validation
Quality control (QC) materials provided by the CDC were
assayed to evaluate the entire methodological procedure.
These materials correspond to a pool of inactivated cord
blood (BP) supplemented with 5% (low), 50% (medium),
and 100% (high) unprocessed cord blood (10). Enzyme
activities were comparable to those reported by the CDC,
and all the assayed enzymes showed a linear dependency
between the enzyme activity and percentage of unprocessed
blood in the DBSs with R2.0.99 (data not shown).
Table 1 - Lysosomal storage disorder enzyme activities of individuals according to age. Data are expressed as the median
¡ median absolute deviation. The percent residual enzyme activities in affected patients according to their age groups
are shown in parentheses.
Enzyme (mmol/h/L)
Controls/Patients Age GAA GLA GALC ABG ASM IDUA
Group 1 0 to 28 days 13.01¡3.34 8.77¡3.08 2.15¡0.91 17.83¡5.03 5.60¡1.33 9.31¡1.71
Group 2 29 days to 5 years 9.59¡2.61 3.69¡0.84 2.31¡0.96 9.72¡2.37 4.44¡1.17 8.29¡2.19
Group 3 5 to 10 years 8.65¡0.94 3.44¡0.77 1.86¡0.77 10.17¡3.27 4.22¡1.44 8.23¡2.94
Group 4 10 to 18 years 6.40¡1.79 3.50¡0.85 1.45¡0.32 9.13¡1.63 3.81¡0.89 7.14¡2.24
Group 5 .18 years 8.11¡1.63 3.32¡1.14 1.36¡0.42 7.71¡2.52 3.75¡0.82 4.64¡2.74
Pompe a 45 years 0.24 (3%)
Pompe b 53 years 0.18 (2%)
Pompe c 30 years 1.19 * (15%)
Pompe d 51 years 0.32 (4%)
Pompe 10 months 0.18 (2%)
Pompe 4 months 0.11 (1%)
Fabry 44 years 0.36 (11%)
Krabbe 17 years 0.19 # (13%)
Gaucher N/A 0.72
Gaucher 26 years 0.78 (10%)
MPS I N/A 0.54
MPS I e 13 years 1.33 (19%)
MPS I f 1 year 1.09 (13%)
GAA = a-glucosidase, ABG = b-glucocerebrosidase, GLA = a-galactosidase, ASM = acid sphingomyelinase, GALC = galactocerebrosidase, and IDUA =
a2L-iduronidase.
*Patient undergoing enzyme replacement therapy (blood collected immediately before enzyme infusion). #Diagnosis pending confirmation by gene
sequencing. N/A = Not available.
Confirmatory enzyme activities using the 4-MU substrate (% of the normal control activity): GAA: a = 2 (4%), b = 2 (3%), c = 0 (0%), and d = 6 (15%)
(reference range = 20 to 60 nmol/h/mg of protein). IDUA: e = 0 (0%) and f = 0 (0%) (reference range = 3 to 19 nmol/h/mg of protein).
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Enzyme activities in newborn and non-newborn
individuals
Enzyme activities in control patients were not normally
distributed for the five age groups and six evaluated
enzymes. Therefore, non-parametric descriptive statistics
and tests were used. As reported in the literature, only
minor discrepancies were found between the population
mean and median (12). The median enzyme activities of the
control and affected patients are listed in Table 1 and shown
in Figure 1. The median activities of the enzymes GAA,
GLA, ABG, and ASM were significantly higher in newborns
(Group 1) than in all the other groups (Mann-Whitney U-
test, p,0.05), findings that were not observed for IDUA and
GALC. For all the evaluated enzymes, patients older than 18
years presented, on average, only ,50% of the median
enzyme activity of newborns. GLA was the enzyme most
affected by age; specifically, patients older than 18 years had
only ,38% of the median activity of newborns.
Diagnosing LSDs in non-newborn patients
In the present study, there were no overlaps between the
enzime activities of the affected and healthy patients of any
age group for the enzymes GAA, GLA, and ABG (Figure 1).
Indeed, all Pompe, Fabry, Gaucher, and Krabbe disease
patients considered in this cohort had enzyme activities
lower than 15% of the median activities of their respective
Figure 1 - Comparison of the enzyme activities (mmol/h/L) between DBS samples from newborns and non-affected adults grouped
according to age and DBS samples from patients with LSDs. *No patients with Niemann-Pick A/B disease were available. This sample
corresponds to a DBS from a healthy patient subjected to protein denaturing conditions (heat inactivation).
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groups (Table 1, in parentheses). A 17-year-old individual
presenting classical clinical symptoms of Krabbe disease was
identified by our genetics service and tested. GALC activity in
this patient was 13% of the median activity of Group 4
(Table 1), and confirmation by gene sequencing is still
pending. No DBSs from Niemann-Pick A/B disease patients
could be obtained. MPS I patients presented 13% (patient aged
1 year) and 19% (patient aged 13 years) of the median IDUA
activity of age-matched controls (Table 1). There was an
overlap between the activity of IDUA in subjects affected by
MPS I and control individuals older than 18 years (Figure 1).
& DISCUSSION
Screening of LSDs by tandem mass spectrometry was
originally developed to provide a suitable methodology for
NBS programs, which require fast and parallel assays (9).
However, there is a demand, particularly in Latin America,
for reliable, inexpensive, and accessible tests to identify not
only asymptomatic newborns but also undiagnosed chil-
dren and adults carrying late-onset alleles (8). Alleles
presenting late-onset clinical manifestations are indeed
common, as demonstrated by pilot studies in Austria,
Italy, and Taiwan (7,13,14).
In the present cohort, the median GAA, GLA, GALC,
ABG, ASM, and IDUA activities in the DBSs of newborns
were comparable to those reported in the literature
(5,7,15,16). It was possible to discriminate between the
enzyme activity in non-affected infants, children, and adults
of any age and the enzyme activity in patients affected with
Pompe, Fabry, Gaucher, and Krabbe diseases (the latter is
still pending confirmation by gene sequencing) as shown in
Table 1 and Figure 1. This finding indicates that, for these
particular diseases, the biochemical assays alone can
provide reliable diagnostics. The overlap between MPS I
patients and non-affected adults aged older than 18 years
(Figure 1) indicates that the identification of patients in
these groups may require other confirmatory biochemical
assays. However, at this age, MPS I clinical symptoms are
usually evident. As the number of screened individuals
increases, group overlaps might occur for other enzyme
measurements. Indeed, heterozygous carriers have approxi-
mately one-half the enzyme activity of normal adults, a
finding that is particularly relevant in screening female
Fabry patients (9). Discerning between adult heterozygotes
who have low enzyme activities and affected patients based
on the enzymes GLA, GALC, and IDUA may eventually be
challenging. Nevertheless, in these cases, a combination of
standard biochemical assays and clinical data should
provide sufficient information to enable accurate diagnoses.
The MS/MS methodology evaluated in this study
introduces further benefits compared with standard fluori-
metric assays as follows: control DBSs provide an external
reference; the methodology allows a more comprehensive
screening of diseases that may have overlapping clinical
manifestations; and several enzyme quantifications can be
performed using a single and robust methodology to
optimize the laboratory routine. Laboratories capable of
performing lysosomal enzyme determinations are scarce in
Latin America. This simple, robust, and inexpensive
methodology will allow more laboratories to perform
lysosomal enzyme determinations. Dried blood spots may
be sent by regular mail in a plain envelope with minimal
financial costs, granting access to specialized genetic tests to
populations located in remote areas of the continent.
Diagnoses will lead to earlier treatment, reducing the
morbidity of the diseases and improving patient survival
and quality of life.
The present study discusses the use of tandem mass
spectrometry assays to screen for Pompe, Fabry, Gaucher,
Krabbe, and Niemann-Pick A/B diseases, as well as MPS I,
in infants, children, and adults. The data presented herein
indicate that this methodology is adequate; however, in
some cases, further clinical and laboratory evaluation may
be necessary. This methodology may become standard in
the near future as the spectra of tested disorders expand to
include other types of LSDs.
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